128 related articles for article (PubMed ID: 11343048)
1. Identification of poor responders to erythropoietin among children undergoing hemodialysis.
Seeherunvong W; Rubio L; Abitbol CL; Montané B; Strauss J; Diaz R; Zilleruelo G
J Pediatr; 2001 May; 138(5):710-4. PubMed ID: 11343048
[TBL] [Abstract][Full Text] [Related]
2. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
3. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
4. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
5. [Study of immutable variables determining rHuEPO dose requirements on hemodialysis patients].
Gascón A; Virto R; Lou LM; Pernaute R; Moreno R; Pérez J; Aladrén MJ; Moragrega B; Castillón E; Gómez R; Vives PJ; Alvarez R; García FJ; Castilla J; Gutiérrez Colón JA
Nefrologia; 2005; 25(5):535-42. PubMed ID: 16392304
[TBL] [Abstract][Full Text] [Related]
6. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
7. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.
Kato A; Tsuji T; Luo J; Sakao Y; Yasuda H; Hishida A
Am J Nephrol; 2008; 28(1):115-21. PubMed ID: 17943020
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and severity of anemia in pediatric hemodialysis patients.
Azhir A; Nasiri J; Gheisari A
Saudi Med J; 2007 Feb; 28(2):249-53. PubMed ID: 17268705
[TBL] [Abstract][Full Text] [Related]
9. Effect of protein-energy malnutrition on erythropoietin requirement in maintenance hemodialysis patients.
Akgul A; Bilgic A; Sezer S; Ozdemir FN; Olcay I; Arat Z; Haberal M
Hemodial Int; 2007 Apr; 11(2):198-203. PubMed ID: 17403171
[TBL] [Abstract][Full Text] [Related]
10. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
[TBL] [Abstract][Full Text] [Related]
11. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998.
Kimmel PL; Greer JW; Milam RA; Thamer M
Semin Nephrol; 2000 Jul; 20(4):335-44. PubMed ID: 10928335
[TBL] [Abstract][Full Text] [Related]
12. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI.
Eschbach JW
Semin Nephrol; 2000 Jul; 20(4):320-9. PubMed ID: 10928333
[TBL] [Abstract][Full Text] [Related]
13. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
Odabas AR; Cetinkaya R; Selcuk Y; Keles S; Bilen H
Panminerva Med; 2003 Mar; 45(1):59-62. PubMed ID: 12682621
[TBL] [Abstract][Full Text] [Related]
14. Possible influence of vitamin D receptor gene polymorphisms on recombinant human erythropoietin requirements in dialysis patients.
Sezer S; Tutal E; Bilgic A; Ozdemir FN; Haberal M
Transplant Proc; 2007; 39(1):40-4. PubMed ID: 17275471
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
18. Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients.
Fischer MA; Morris CA; Winkelmayer WC; Avorn J
Arch Intern Med; 2007 Apr; 167(8):840-6. PubMed ID: 17452549
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
